| Filed On | Filing |
|---|---|
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition
Submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in October 2026 seeking accelerated approval for CNM-Au8® in amyotrophic lateral sclerosis (ALS) |
| 20 Oct 2026 |
8-K: Entry into a Material Definitive Agreement
Intermediate-sized Expanded Access Protocol for CNM-Au8 in Amyotrophic Lateral Sclerosis (ALS) |
| 19 Oct 2026 |
8-K: Other Events
NDA submission seeks accelerated approval of CNM-Au8 based on neurofilament light chain biomarker data and clinical outcomes |
| 16 Sep 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
This Securities Purchase Agreement (this “Agreement”) is dated as of September 15, 2026, between Clene Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its success... |
| 14 Aug 2026 |
8-K: Results of Operations and Financial Condition
Clene expects to submit a New Drug Application for CNM-Au8® in ALS under the accelerated approval pathway in early fourth quarter of 2026 |
| 10 Aug 2026 |
8-K: Regulation FD Disclosure; Other Events
Survival benefit is concentrated in participants with NfL biomarker response: CNM-Au8®-treated patients whose NfL declined or stabilized lived significantly longer than concurrently randomized controls |
| 22 May 2026 |
8-K: Entry into a Material Definitive Agreement; Departure/Election of Directors or Officers; Compensation +1 more
1. Purpose. The purpose of this Amended 2020 Stock Plan (the “Plan”) is to enable Clene Inc., a Delaware corporation (the “Company”), to attract and retain the services of (i) selected employees, officers, and directors of the Company or... |
| 14 May 2026 |
8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition
After successful completion of FDA Type C meeting, Clene expects to submit an NDA for CNM-Au8® under the accelerated approval pathway in the third quarter of 2026 |
| 05 May 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
Clene Inc., a Delaware corporation (the “Company”), proposes to sell to the several underwriters named in Schedule I hereto (the “Underwriters”), for whom you are acting as representative (the “Representative”), an aggregate of 1,000,000... |
| 04 May 2026 |
8-K: Regulation FD Disclosure; Other Events
FDA stated that the “proposed data may be capable of supporting the submission and review of an [NDA] under the accelerated approval pathway” for CNM-Au8 based on neurofilament light (NfL) biomarker data |
| 17 Mar 2026 |
8-K: Entry into a Material Definitive Agreement
Name: New York University, on behalf of its Grossman School of Medicine |
| 12 Mar 2026 |
8-K: Results of Operations and Financial Condition
In-person Type C FDA meeting scheduled by end of the first quarter of 2026 to discuss the latest CNM-Au8® data submitted; Clene expects formal written meeting minutes early in the second quarter 2026 |
| 24 Feb 2026 |
8-K: Other Events
Operating capital runway sufficient into the fourth quarter of 2026 |
| 13 Jan 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
This Securities Purchase Agreement (this “Agreement”) is dated as of January 8, 2026, between Clene Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors... |
| 12 Jan 2026 |
8-K: Other Events
The FDA has granted an in-person Type C meeting during the first quarter of 2026 |
| 03 Dec 2025 |
8-K: Regulation FD Disclosure
On December 3, 2025, Clene Inc. (the “Company”) hosted a conference call and webcast to provide an update on its CNM-Au8® program in amyotrophic lateral sclerosis (“ALS”). A copy of the presentation is furnished as Exhibit 99.1 to this C... |
| 03 Dec 2025 |
8-K: Other Events
FDA recommended biomarker analyses show statistically significant reductions in NfL and GFAP in participants treated with CNM-Au8 |
| 13 Nov 2025 |
8-K: Results of Operations and Financial Condition
As the U.S. Food and Drug Administration (FDA) proposed, Clene is concluding analyses of its ALS biomarker data with completion planned shortly |
| 17 Oct 2025 |
8-K: Other Events
200 South Orange Avenue, Suite 2600 | Orlando, FL 32801 | T 407.425.8500 | F 407.244.5288 |
| 14 Oct 2025 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
On October 14, 2025, Clene Inc. (“the Company”) released an updated corporate presentation (the “Corporate Presentation”) on its website, invest.clene.com, containing the Company’s preliminary unaudited (i) balance of cash and cash equiv... |
Loading...